↓ Skip to main content

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib

Overview of attention for article published in Journal of Ophthalmic Inflammation and Infection, June 2015
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#43 of 191)
  • Good Attention Score compared to outputs of the same age (66th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
28 Mendeley
Title
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
Published in
Journal of Ophthalmic Inflammation and Infection, June 2015
DOI 10.1186/s12348-015-0049-9
Pubmed ID
Authors

Dafina Draganova, Joseph Kerger, Laure Caspers, François Willermain

Abstract

We report a case of severe bilateral panuveitis during melanoma therapy with a combination of Dabrafenib, a B-raf (BRAF) inhibitor, and Trametinib, a mitogen/extracellular signal-regulated kinase (MEK) inhibitor. Both of these drugs are effectors in the mitogen-activated protein kinase (MAPK) pathway, which plays an important role in the physiopathology of melanoma. Dabrafenib and Trametinib have shown improved survival of patients with metastatic melanoma but they have also been associated with the development of uveitis. Our patient was a 55-year-old woman with metastatic melanoma who presented with sudden onset of bilateral painless visual loss. She had been treated with Dabrafenib and Trametinib. Trametinib was discontinued at the onset of symptoms but there was no improvement. Ophthalmological examination revealed severe bilateral non-granulomatous panuveitis, with choroidal thickening, chorio-retinal folds, and multiple serous retinal detachments (SRDs). Topical corticosteroid treatment was initiated, and Dabrafenib was discontinued. A good response was obtained with a recovery of visual acuity of 20/25 on both eyes and an almost complete resolution of the SRDs. This case highly suggests that MAPK pathway inhibition can lead to severe uveitis. Dabrafenib and Trametinib could have both played a role in inducing the disease. Further studies are needed to evaluate the possible role of the combination of these drugs in inducing uveitis and SRD.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 4%
Unknown 27 96%

Demographic breakdown

Readers by professional status Count As %
Student > Doctoral Student 7 25%
Other 6 21%
Student > Ph. D. Student 2 7%
Student > Postgraduate 2 7%
Student > Master 2 7%
Other 3 11%
Unknown 6 21%
Readers by discipline Count As %
Medicine and Dentistry 18 64%
Nursing and Health Professions 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Unknown 8 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2023.
All research outputs
#7,477,246
of 23,505,669 outputs
Outputs from Journal of Ophthalmic Inflammation and Infection
#43
of 191 outputs
Outputs of similar age
#87,511
of 267,729 outputs
Outputs of similar age from Journal of Ophthalmic Inflammation and Infection
#1
of 6 outputs
Altmetric has tracked 23,505,669 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 191 research outputs from this source. They receive a mean Attention Score of 3.3. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,729 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them